Roivant Sciences Ltd. reported a net loss attributable to the company of $171.981 million for the year ended March 31, 2025, compared to a net income of $4.348 billion for the previous year. The loss from continuing operations, net of tax, amounted to $729.764 million for the year ended March 31, 2025, a significant downturn from the income of $4.546 billion reported for the year ended March 31, 2024. This result translates to a loss of $0.75 per common share for the year ended March 31, 2025, compared to an income of $5.95 per share for the previous year. The company's cash, cash equivalents, and restricted cash decreased to $2.726 billion as of March 31, 2025, from $6.506 billion a year earlier. Despite this, Roivant reported consolidated cash, cash equivalents, restricted cash, and marketable securities of $4.9 billion as of March 31, 2025, which is expected to support the company's cash runway into profitability. Roivant also undertook a share repurchase program, buying back $1.3 billion of its shares by March 31, 2025, which reduced the outstanding shares by 14% from the previous year. The company continues to focus on its late-stage clinical pipeline, highlighted by the development of brepocitinib and positive data from its myasthenia gravis study, alongside the expansion of IMVT-1402 into new indications.